Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents: Difference between revisions
Jump to navigation
Jump to search
Hardik Patel (talk | contribs) (/* Current Modification of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents {{cite journal| author=McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberge...) |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} | {{CMG}} | ||
{{Hyperlipidemia}} | |||
{{ | |||
==Overview== | ==Overview== |
Revision as of 18:53, 19 February 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Lipoprotein Disorders Microchapters |
Overview
Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations.
NCEP Recommendations for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents
Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents [1] (DO NOT EDIT)
“ |
|
” |
Current Modifications of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents [1] (DO NOT EDIT)
“ |
|
” |
References
- ↑ 1.0 1.1 McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP; et al. (2007). "Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing". Circulation. 115 (14): 1948–67. doi:10.1161/CIRCULATIONAHA.107.181946. PMID 17377073.